Tuesday, December 23, 2025 | 11:21 AM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Page 27 - Usfda

Tech Mahindra arm leverages AI for potential Covid-19 therapeutic drugs

Makers Lab does molecular docking studies of 19 FDA approved ligands and anti-virals. technique enables search for therapeutically potent drugs and molecules in real-time

Tech Mahindra arm leverages AI for potential Covid-19 therapeutic drugs
Updated On : 15 May 2020 | 9:01 PM IST

Gilead enters licensing pact with 5 drug firms in India, Pak for remdesivir

According to the agreement the companies Cipla, Hetero Labs, Jubilant Life Sciences, Mylan, and Pakistan based Ferozsons Labs, to manufacture and sell remdesivir in 127 countries

Gilead enters licensing pact with 5 drug firms in India, Pak for remdesivir
Updated On : 13 May 2020 | 10:08 AM IST

Jubilant Life inks non-exclusive licensing pact with Gilead for Remdesivir

The drug, which is an injectable, got emergency approval from the US drug regulator recently.

Jubilant Life inks non-exclusive licensing pact with Gilead for Remdesivir
Updated On : 13 May 2020 | 12:30 AM IST

Centre keen on testing Gilead's remdesivir to combat coronavirus

The USFDA has recently given an emergency approval to the drug for use on coronavirus patients

Centre keen on testing Gilead's remdesivir to combat coronavirus
Updated On : 11 May 2020 | 2:30 AM IST

USFDA authorises emergency use of antigen test to diagnose, treat Covid-19

According to Johns Hopkins University, the United States has over 1.3 million confirmed cases, with the death toll at 78,320

USFDA authorises emergency use of antigen test to diagnose, treat Covid-19
Updated On : 10 May 2020 | 7:29 AM IST

Dr Reddy's gets USFDA inspection closure report fo Srikakulam unit

The plant is one of the company's three units that were served a warning letter in November 2015 for not following the prescribed operational and manufacturing quality standards

Dr Reddy's gets USFDA inspection closure report fo Srikakulam unit
Updated On : 08 May 2020 | 9:19 PM IST

Blood thinners may boost survival rates of coronavirus patients: Study

The Washington Post reported that the results of the analysis, conducted over 2,733 patients, were published on Wednesday in the Journal of the American College of Cardiology

Blood thinners may boost survival rates of coronavirus patients: Study
Updated On : 08 May 2020 | 1:48 PM IST

US targets fraud in coronavirus antibody test market with tighter rules

The FDA said it would share information on its website and with potential buyers of these tests

US targets fraud in coronavirus antibody test market with tighter rules
Updated On : 05 May 2020 | 12:01 PM IST

Not just bigwigs, Mid-rung local players join coronavirus vaccine race

With vaccines of some firms already in animal trial phase, developers say that if all goes well, India could have a vaccine by next year

Not just bigwigs, Mid-rung local players join coronavirus vaccine race
Updated On : 02 May 2020 | 11:10 PM IST

How remdesivir, new hope for Covid-19 patients, was resurrected

The drug failed as a treatment for hepatitis and Ebola. With federal funding, scientists trained it on the coronavirus.

How remdesivir, new hope for Covid-19 patients, was resurrected
Updated On : 02 May 2020 | 7:41 PM IST

USFDA okays emergency use of Gilead drug for hospitalised Covid-19 patients

Gilead CEO Daniel O'Day has announced that the company is donating 1.5 million vials of the medicine

USFDA okays emergency use of Gilead drug for hospitalised Covid-19 patients
Updated On : 02 May 2020 | 11:18 AM IST

FDA's lax blood test rules open US market to dubious vendors: Report

The rush to obtain test kits follows the FDA's unprecedented decision last month to allow any company to sell antibody tests in the US without prior review by the agency

FDA's lax blood test rules open US market to dubious vendors: Report
Updated On : 01 May 2020 | 4:46 PM IST

Lupin gets inspection closure report from USFDA for Pithampur plant

Lupin Managing Director Nilesh Gupta, said the company has received the EIR for the plant with Voluntary Action Indicated (VAI) status

Lupin gets inspection closure report from USFDA for Pithampur plant
Updated On : 30 Apr 2020 | 1:12 PM IST

Diversified model, US outlook to help Dr Reddy's stock trade better

The company has multiple growth engines given its focus on India/emerging markets and limited competition products in the US

Diversified model, US outlook to help Dr Reddy's stock trade better
Updated On : 29 Apr 2020 | 2:01 AM IST

Battling Covid-19: Start-ups chip in to resolve India's ventilator crisis

Domestic firms are also sourcing ventilator parts from within the country to manufacture ventilators at a much lower cost

Battling Covid-19: Start-ups chip in to resolve India's ventilator crisis
Updated On : 27 Apr 2020 | 11:00 PM IST

Covid-19: US FDA warns against use of hydroxychloroquine outside hospitals

Among some of side effects, heart rhythm abnormalities developed in most of the 84 coronavirus patients treated with hydroxychloroquine

Covid-19: US FDA warns against use of hydroxychloroquine outside hospitals
Updated On : 25 Apr 2020 | 9:36 PM IST

US FDA clears Aurobindo Pharma Unit IV, reverts classification to VAI

The latest classification, VAI, suggests that though certain objectionable conditions were found during the review, they did not warrant any further regulatory action

US FDA clears Aurobindo Pharma Unit IV, reverts classification to VAI
Updated On : 21 Apr 2020 | 1:44 PM IST

USFDA may have dropped standards too far in hunt for Covid-19 drug: Report

Although some rules can be waived in an emergency, the FDA dropped its quality-control standards too far as it scoured the world for scarce supplies of chloroquine drugs.

USFDA may have dropped standards too far in hunt for Covid-19 drug: Report
Updated On : 17 Apr 2020 | 12:51 PM IST

Lupin pharma receives EIR from USFDA for Mandideep Unit II facility

The inspection at the facility was carried out by the US Food and Drug Administration between November 26, 2018

Lupin pharma receives EIR from USFDA for Mandideep Unit II facility
Updated On : 15 Apr 2020 | 12:21 PM IST

Clearance from US drug regulator key for Lupin to sustain stock gains

The recent gains came on Monday after the company received the USFDA approval for its Nagpur facility

Clearance from US drug regulator key for Lupin to sustain stock gains
Updated On : 15 Apr 2020 | 3:07 AM IST